correspondence

Intensity-Modulated Radiation Therapy for Prostate Cancer To the Editor: Mitchell (Oct. 24 issue)1 highlights the fact that reimbursement drives behavior in physicians who treat prostate cancer. Yet, we are concerned that she may be perpetuating a myth with the statement “. . . evidence suggests that for low-risk disease, the three primary definitive treatments are clinically equivalent when measured in terms of survival.” Although it is true that survival rates associated with these treatments are similar, Mitchell did not point out that that no randomized trial in the era of prostate-specific antigen (PSA) testing has ever shown that definitive treatment of low-risk prostate cancer, as compared with observation, provides benefit. Furthermore, all definitive treatments are associated with some negative effects on quality of life.2,3 Another important finding associated with Mitchell’s study was that surveillance rates decreased during the ownership period among “selfreferring urologists in private practice” (P

Intensity-modulated radiation therapy for prostate cancer.

Intensity-modulated radiation therapy for prostate cancer. - PDF Download Free
291KB Sizes 2 Downloads 0 Views